| Document |
Document Title |
|
WO/2016/137411A1 |
The present invention relates to the preparation of stable topical pharmaceutical composition comprising ibuprofen and lidocaine. Preferably, the composition is topical spray.
|
|
WO/2016/137352A1 |
A pharmaceutical composition having an analgesic, anaesthetic and antiseptic action, a method for producing the pharmaceutical composition and a method for the treatment of otitis and other ear injuries. The group of inventions relate...
|
|
WO/2016/126217A1 |
The present invention relates to the preparation of stable pharmaceutical compositions comprising benzydamine hydrochloride as an anti-inflammatory agent, cetylpyridinium as an quaternary ammonium compound of antiseptics, lidocaine hydro...
|
|
WO/2016/124162A1 |
A propanidid pharmaceutical composition, comprising propanidid, oil for injection, phospholipid, and water for injection, the parts by weight of propanidid being 1 to 10, the parts by weight of oil for injection being 10 to 60, the parts...
|
|
WO/2016/123270A1 |
This invention provides compositions, kits containing compositions, and methods for their use in treating subjects with pain. Instant compositions comprise two or more long acting aminoamide local anesthetics, at least one NSAID, at leas...
|
|
WO/2016/117538A1 |
This anesthesia device for measuring the hydrogen concentration in an anesthetic gas that contains hydrogen gas is characterized by being provided with an anesthetic gas preparation circuit (3) which generates the anesthetic gas by mixin...
|
|
WO/2016/118040A1 |
The inventions relate to the pharmaceutical industry, including pharmaceutical compositions forming the base of gels, and methods for producing gels which are intended mainly for preventing and/or treating anal fissures, haemorrhoids and...
|
|
WO/2016/110865A1 |
The invention relates to the compounds of formula I and II and its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compoun...
|
|
WO/2016/103999A1 |
[Problem] To provide: a package for a patch, said package assuring a high temporal stability of a drug; a patch product comprising the patch and a packaging bag; and a method for manufacturing the patch product. [Solution] A patch produc...
|
|
WO/2016/074055A1 |
Filmogenic compositions are described for topical anaesthetic bioadhesives (TABs) comprising a) a xanthan biopolymer matrix selected from Xanthomonas species and pathovars, including Xanthomonas campestris pathovars campestris and maninh...
|
|
WO/2016/075239A1 |
The invention relates to aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amide derivatives of general formula (l),which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders relat...
|
|
WO/2016/075365A1 |
The present invention relates to compositions for facilitating absorption and distribution of α2 -adrenergic agonists, where said composition comprises a substituted benzofuroquinolizine and a α2 -adrenoceptor agonist selected from sub...
|
|
WO/2016/070826A1 |
A ropivacaine sustained-release gel formulation, and preparation method and use thereof, the gel formulation comprising 1-20 wt% of ropivacaine and 14-22 wt% of poloxamer 407, and the remainder being water or a salt solution.
|
|
WO/2016/047664A1 |
The present invention addresses the problem of providing a propofol-containing oil-in-water emulsion composition that is highly stable even when filled into a plastic container, and a method for producing the same. The present invention ...
|
|
WO/2016/037250A1 |
The present invention relates to a method for purifying jambu (Spilanthes acmella (L.)L ) extract, the thus obtained purified jambu extract, an anaesthetic composition and a bioadhesive containing purified jambu extract. Another object o...
|
|
WO/2016/034079A1 |
The present invention relates to a pharmaceutical preparation of a compound of formula (I) or stereoisomer, pharmaceutically acceptable salt, prodrug thereof, and a novel method for general anesthesia or sedative for mammals. Also provid...
|
|
WO/2016/015581A1 |
Disclosed are a dimethylphenylammonium long-chain compound, a preparation, a self-assembled structure and a use thereof. The compound can have an ultra-long-acting anaesthetic effect, is a N-diethylaminoacetyl-2,6-dimethylphenylammonium ...
|
|
WO/2016/011943A1 |
The present invention relates to a new benzodiazepine derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and use thereof. The benzodiazepine derivative and the pharmaceutically acceptable salt thereof of t...
|
|
WO/2015/198456A1 |
The present invention provides a rocuronium formulation having excellent stability. This formulation includes rocuronium and a buffer solution, and has a pH adjusted to 3.5 or less (for example, 2.5-3.5). The buffer solution may be a cit...
|
|
WO/2015/185208A1 |
The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity,...
|
|
WO/2015/164781A1 |
The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds, including an important class of hydrophobic anesthetics. Formulations an...
|
|
WO/2015/164756A1 |
The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds, including an important class of hydrophobic anesthetics. Formulations an...
|
|
WO/2015/164859A1 |
The disclosure relates to intravenous formulations of GLYX peptides for treating CNS Disorders such as depression, neuropathic pain, or anxiety.
|
|
WO/2015/161180A1 |
The invention relates to the fields of pharmacology and medicine, and provides anesthetic compositions and methods for the treatment of pain using compositions comprising Tea tree oil and one or more additional agent. The invention relat...
|
|
WO/2015/154778A1 |
The present invention relates to the combination of an analgesic compound and a phospholipid membrane stabilising compound for safer pain relief. The invention further relates to use of the combination of compounds for pain relief in a s...
|
|
WO/2015/140736A1 |
Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoi...
|
|
WO/2015/132985A1 |
The present invention provides an emulsion composition of excellent physical stability over time and suitable safety, which is usable in concentration-increase applications, and characterized by the inclusion of sevoflurane, a fatty acid...
|
|
WO/2015/128419A1 |
The invention relates to a method for producing a flurane complex, comprising the following steps: producing an aqueous solution of sulfobutylether-β-cyclodextrin (SBECD); controlling the temperature of said solution to a temperature of...
|
|
WO/2015/126942A1 |
Methods for providing post-operative pain control or relief, without a medically significant degree of numbness, to a patient are disclosed. Methods include, for example, topically administering a paste or ointment comprising bicarbonate...
|
|
WO/2015/127451A1 |
A compound for treatment of pain comprising a single multivalent/multifunctional ligand with agonist activity at opioid receptors and with antagonist activity at NK-1 receptors, joined by a linker. Also disclosed is a pharmaceutical comp...
|
|
WO2015120821A1 |
Disclosed are water-soluble propofol derivatives, preparation method thereof, anaesthesia method using same, use thereof as prodrugs and use thereof for preparing vein dope medicines. The water-soluble propofol derivatives have a general...
|
|
WO/2015/113057A1 |
Compounds (I), processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the FP, DP, EP1, EP4, I...
|
|
WO/2015/112754A1 |
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or...
|
|
WO/2015/101693A1 |
The invention relates to a composition and/or a kit for the preparation thereof and/or a combined preparation comprising a free base or any of the pharmaceutically acceptable salts thereof, in which the free base has formula (I), (in whi...
|
|
WO/2015/103450A1 |
An improved local anesthetic solution with diminished bitter taste includes an anesthetic agent, an anesthetic solution vehicle, and a bitterness suppressant. The bitterness suppressant includes one or more compounds selected from the gr...
|
|
WO/2015/096551A1 |
An N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, a preparation method and an application. The structure of the compound is represented by formula (I). The compound can generate a rapid and rever...
|
|
WO/2015/097475A1 |
The present invention relates to compounds of formula (I) shown below: wherein Q is as defined herein. The compounds of formula (I) act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The pr...
|
|
WO/2015/095128A1 |
The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these ...
|
|
WO/2015/082857A1 |
The invention relates to a combination of two compounds stemming from fatty acids and to the cosmetic and dermatological uses of said combination, the latter being a combination of at least one compound (a) stemming from the condensation...
|
|
WO/2015/079240A1 |
The present invention relates to administration of a dinucleoside polyphosphate analogue or a pharmaceutically acceptable salt thereof, topically in a formulation comprising a suitable excipient or using a device for transdermal delivery...
|
|
WO/2015/074730A1 |
The present invention relates to a composition, especially pharmaceutical composition, preferably in the form of a lubricant gel and/or lubricant medium, preferably for use as a (local) antiseptic and/or (local) anaesthetic, especially f...
|
|
WO/2015/061910A1 |
The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a drug such as a local anesthetic, an NSAID, or a corticosteriod; and s...
|
|
WO/2015/006828A9 |
The invention relates to a composition and method for increasing blood pressure, including a low pain or analgesic state or hypotensive anaesthesia in a subject that has suffered a life threatening hypotension or shock or reducing hypofu...
|
|
WO/2015/024420A1 |
A local anesthesia pain-relieving time-delay agent. Each unit dosage form thereof comprises: 0.5 to 20 mg of composite vitamin B, 10 to 20 mg of methylene blue, 10 to 100 mg of dexamethasone, 2 to 100 ml of 5% sodium bicarbonate, and 0.9...
|
|
WO/2015/024100A1 |
A method of providing anesthesia and organ-protection to a subject in need thereof comprises co-administering to the subject a non-anesthetic protective gas in an amount effect to provide organ protection, and a liquid anesthetic agent i...
|
|
WO/2015/023816A1 |
The present invention is directed to (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-
yl-propan-1-one (L)-(+) tartrate salt, a pharmaceutical composition comprising said salt, a process for making said salt, and the use of sa...
|
|
WO/2014/127475A9 |
A composition for the treatment of perianal disorders. In particular, the composition includes three components: a) an analgesic, b) a cryoprotective agent and c) a muscle relaxant.
|
|
WO/2015/006827A1 |
The invention relates to a composition and method for inducing whole-body arrest, a coma-like state or a sleep state, a hypotensive state or a low pain or analgesic state. The composition comprises (i) a compound selected from at feast o...
|
|
WO/2015/001995A1 |
Provided is a rocuronium preparation that makes it possible to suppress vascular pain. This rocuronium preparation is characterized by containing rocuronium and a buffer and having titratable acidity of 100 mEq or less. The buffer may be...
|
|
WO/2014/201541A1 |
Disclosed are liquid compositions suitable for topical administration and for use with a non-aerosol pump, wherein actuation of the pump produces a foam, the composition comprising: (a) about 1% to about 8% (w/w) foam booster; (b) about ...
|
